

Juanita R. Brooks (CA Bar No. 75934) (brooks@fr.com)  
FISH & RICHARDSON P.C.  
12390 El Camino Real  
San Diego, CA 92130  
Telephone: (858) 678-5070 / Fax: (858) 678-5099

Craig E. Countryman (CA Bar No. 244601) (countryman@fr.com)  
FISH & RICHARDSON P.C.  
555 W. 5th Street, 31st Floor  
Los Angeles, California 90013  
Telephone: (213) 533-4240 / Fax: (213) 996-8304

Jonathan E. Singer (CA Bar No. 187908) (singer@fr.com)  
Michael J. Kane (kane@fr.com)  
FISH & RICHARDSON P.C.  
60 South Sixth Street, Suite 3200  
Minneapolis, MN 55402  
Telephone: (612) 335-5070 / Fax: (612) 288-9696

Susan M. Coletti (coletti@fr.com)  
Elizabeth M. Flanagan (eflanagan@fr.com)  
FISH & RICHARDSON P.C.  
222 Delaware Avenue, 17th Floor  
Wilmington, DE 19899  
Telephone: (302) 652-5070 / Fax: (302) 652-0607

Attorneys for Plaintiffs  
ALLERGAN USA, INC. and ALLERGAN INDUSTRIE, SAS

Donald G. Norris (SBN 90000)  
Douglas F. Galanter (SBN 93740)  
Norris & Galanter LLP  
523 W. Sixth St., Suite 716  
Los Angeles, CA 90014  
Tel: 213-232-0855/ Fax: 213-286-9499  
dnorris@norgallaw.com  
dgalanter@norgallaw.com

William F. Cavanaugh (SBN 133461)  
Edward R. Tempesta (*pro hac vice* application forthcoming)  
William F. Schmedlin (*pro hac vice* application forthcoming)  
Patterson Belknap Webb & Tyler LLP  
1133 Avenue of the Americas  
New York, NY 10036  
Telephone: (212) 336-2000/ Fax: (212) 336-2222  
wcavanaugh@pbwt.com  
ertempesta@pbwt.com  
wschmedlin@pbwt.com

Attorneys for Defendants  
MEDICIS AESTHETICS, INC., MEDICIS PHARMACEUTICAL CORP.,  
VALEANT PHARMACEUTICALS NORTH AMERICA LLC,  
VALEANT PHARMACEUTICALS INTERNATIONAL,  
and VALEANT PHARMACEUTICALS INTERNATIONAL, INC.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA**

ALLERGAN USA, INC. and  
ALLERGAN INDUSTRIE, SAS,

Plaintiffs,

v.

MEDICIS AESTHETICS, INC.,  
MEDICIS PHARMACEUTICAL CORP.,  
VALEANT PHARMACEUTICALS  
NORTH AMERICA LLC,  
VALEANT PHARMACEUTICALS  
INTERNATIONAL and  
VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

Defendants.

Case No. 8:13-cv-01436 AG (JPRx)

**PROTECTIVE ORDER**

**1. PURPOSE AND LIMITS OF THIS ORDER**

Discovery in this action is likely to involve confidential, proprietary, or private information requiring special protection from public disclosure and from use for any purpose other than this litigation. Thus, the Court enters this Protective Order. This Order does not confer blanket protections on all disclosures or responses to discovery, and the protection it gives from public disclosure and use extends only to the specific material entitled to confidential treatment under the applicable legal principles. This Order does not automatically authorize the filing under seal of material designated under this Order. Instead, the parties must comply with L.R. 79-5.1 if they seek to file anything under seal. This Order does not govern the use at trial of material designated under this Order.

**2. DEFINITIONS**

**2.1 “CONFIDENTIAL” Information or Items:** information (regardless of how it is generated, stored or maintained) or tangible things of the Producing Party that is not publicly known and which the Producing Party would not normally reveal to third parties or, if disclosed, would require such third parties to maintain in



1 confidence, including without limitation information that the Producing Party  
2 claims in good faith to constitute or relate to (i) trade secrets under applicable law;  
3 (ii) highly confidential and/or proprietary information, such as without limitation,  
4 any Premarket Approval Application (“PMA”), research and development  
5 information (including, for example, laboratory notebooks, research plans, market  
6 and demographic research, and product and advertising development),  
7 commercially sensitive competitive information (including, for example, business  
8 plans, business strategies, negotiations, and license agreements), financial  
9 information (including, for example, budgeting, accounting, sales figures,  
10 forecasts, and advertising expenditures), business relationship information  
11 (including, for example, information pertaining to potential and/or existing  
12 customers, competitors, suppliers, distributors, affiliates, subsidiaries, and parents),  
13 personnel information (including, for example, compensation, evaluations and  
14 other employment information), non-public patent prosecution information  
15 (including, for example, present or future patent applications that are not publicly  
16 accessible), and non-public regulatory filings; and (iii) information that is subject  
17 to regulation by state, federal or foreign privacy laws such as, without limitation,  
18 the Health Insurance Portability and Accountability Act.

19 **2.2 Designating Party:** A party or non-party that designates information or  
20 items that it produces in disclosures or in response to discovery as  
21 “CONFIDENTIAL.”

22 **2.3 Disclosure or Discovery Material:** all items or information, regardless of  
23 the medium or manner in which it is generated, stored or maintained (including,  
24 among other things, documents, testimony, transcripts, and tangible things), that  
25 are produced, served, or generated during discovery in this action, including, for  
26 example, answers to interrogatories, responses to requests for admissions,  
27 responses to requests for production, subpoenas, declarations, affidavits, and  
28



1 deposition testimony or transcripts, and all copies, extracts, summaries,  
2 compilations, designations and portions thereof.

3 **2.4 Producing Party:** A party or non-party that produces Disclosure or  
4 Discovery Material in this action.

5 **2.5 Receiving Party:** A party or non-party that receives Disclosure or  
6 Discovery Material in this action.

7 **2.6 Scope:** The scope of this Order shall be understood to encompass not only  
8 Disclosure or Discovery Material that is expressly designated as  
9 CONFIDENTIAL, but also any information derived therefrom, including all  
10 copies, excerpts and summaries thereof, whether partial or complete, as well as  
11 testimony and oral conversations which reveal all or part of that information.

### 12 **3. DESIGNATING PROTECTED MATERIAL**

13 **3.1 Over-Designation Prohibited.** Any party or non-party who designates  
14 information or items for protection under this Order as “CONFIDENTIAL” must  
15 do so in good faith.

#### 16 **3.2 Manner and Timing of Designations.**

17 **3.2.1 Documents.** In the case of documents or any other tangible things  
18 produced, designation under this Order requires the Producing Party to affix the  
19 legend “CONFIDENTIAL” to each designated confidential page of the document  
20 and on the cover or in a prominent place on any other tangible thing that contains  
21 protected material, or, in the case of natively-produced files, in the file name,  
22 before production of the document or tangible thing.

23 **3.2.2 Inspections.** A party or non-party that makes original documents or  
24 materials available for inspection need not designate them for protection until after  
25 the inspecting party has identified which material it would like copied and  
26 produced. During the inspection and before the designation, all material shall be  
27 treated as CONFIDENTIAL. After the inspecting party has identified the  
28



1 documents it wants copied and produced, the Producing Party must designate the  
2 documents, or portions thereof, that qualify for protection under this Order.

3 **3.2.3 Testimony.** For testimony given in deposition or other proceeding, the  
4 Producing Party shall specify all protected testimony and the level of protection  
5 being asserted. It may make that designation during the deposition or proceeding,  
6 or may invoke, on the record or by written notice to all parties on or before the  
7 next business day, a right to have up to 21 days from the deposition or proceeding  
8 to make its designation. Designated testimony shall be bound in a separate volume  
9 and marked CONFIDENTIAL by the reporter. The Producing Party shall inform  
10 the court reporter of these requirements. Any transcript that is prepared before the  
11 expiration of the 21-day period for designation shall be treated during that period  
12 as if it had been designated CONFIDENTIAL unless otherwise agreed. After the  
13 expiration of the 21 day period, the transcript shall be treated only as actually  
14 designated.

15 Parties shall give advance notice if they expect a deposition or other  
16 proceeding to include designated material so that the other parties can ensure that  
17 only authorized individuals are present at those proceedings when such material is  
18 disclosed or used. The use of a document as an exhibit at a deposition shall not in  
19 any way affect its designation.

20 **3.2.4 Inadvertent Failures to Designate.** An inadvertent failure to  
21 designate does not, standing alone, waive protection under this Order. Upon  
22 timely assertion or correction of a designation, all recipients must make reasonable  
23 efforts to ensure that the material is treated according to this Order.

#### 24 **4. CHALLENGING CONFIDENTIALITY DESIGNATIONS**

25 All challenges to confidentiality designations shall proceed under L.R. 37-1  
26 through L.R. 37-4.



1 **5. ACCESS TO DESIGNATED MATERIAL**

2 **5.1 Basic Principles.** A Receiving Party may use designated material only  
3 for this litigation. Designated material and the information derived from such  
4 material shall be kept confidential and shall not be given, shown, made available,  
5 discussed, or otherwise communicated in any manner, either directly or indirectly,  
6 to any person not authorized to receive the information under the terms of this  
7 Order.

8 **5.2 Access to CONFIDENTIAL Material Without Further Approval.**  
9 Unless otherwise ordered by the Court or permitted in writing by the Producing  
10 Party, a Receiving Party may disclose any material designated CONFIDENTIAL  
11 only to:

12 **5.2.1** The Receiving Party's outside counsel of record in this action  
13 and employees of outside counsel of record to whom disclosure is  
14 reasonably necessary;

15 **5.2.2** The Court and its personnel;

16 **5.2.3** Outside court reporters and their staff, professional jury or trial  
17 consultants, and professional vendors to whom disclosure is reasonably  
18 necessary, including, but not limited to, graphics or design services,  
19 translation or interpretation services, and third-party contractors and their  
20 employees involved in document management or copying services for this  
21 action;

22 **5.2.4** Approved consultants or experts, excluding employees, officers  
23 or directors of a named party or owners of more than a two-percent interest  
24 in a named party, retained by any of the parties or their counsel to consult or  
25 testify in the litigation;



1           **5.2.5** During their depositions, witnesses in the action who are  
 2           directors, officers, employees or corporate designees of the Producing Party  
 3           under Fed. R. Civ. P. 30(b)(6); and

4           **5.2.6** During their depositions, witnesses in this action (including, but  
 5           not limited to, individuals who were formerly director, officers, employees,  
 6           or experts of the Producing Party, but only if the CONFIDENTIAL  
 7           information was in existence during the period of his or her service or  
 8           employment and it is established that the witness was involved in the project  
 9           to which the CONFIDENTIAL information relates so that it is reasonable  
 10          the witness had access to it during the course of his or her service or  
 11          employment) and their counsel, provided that the information was authored,  
 12          created by, addressed to, received by, signed by, or is otherwise established  
 13          to have been known to the witness.

14          **5.3 Procedures for Approving or Objecting to Disclosure of Material to**  
 15          **In-House Counsel or Experts.** Unless agreed to in writing by the Producing  
 16          Party:

17               **5.3.1** A party seeking to disclose to in-house counsel any material  
 18               designated CONFIDENTIAL must first make a written request to the  
 19               Producing Party providing the full name of the in-house counsel, the city and  
 20               state of such counsel's residence, such counsel's current and reasonably  
 21               foreseeable future primary job duties and responsibilities, and an executed  
 22               Agreement to be Bound (Exhibit A). For each party in this litigation, up to  
 23               three in-house counsel may be designated to receive CONFIDENTIAL  
 24               information under this Order, subject to Section 6.

25               For Allergan: William N. Scarff, Jr.; Debra D. Condino; Donald P.  
 26               Bunnin

27               For Valeant/Medicis: Denis Polyn; Toan Vo  
 28



1           **5.3.2** A party seeking to disclose to an expert retained by outside  
2 counsel of record any information or item that has been designated  
3 CONFIDENTIAL must first make a written request to the Producing Party  
4 that (1) sets forth the full name of the expert and the city and state of his or  
5 her primary residence, (2) attaches a copy of the expert's current resume, (3)  
6 identifies the expert's current employer(s), (4) identifies consulting activities  
7 and job history for the past three years, and (5) includes an executed  
8 Agreement to Be Bound (Exhibit A). If the expert believes any of this  
9 information at (4) is subject to a confidentiality obligation to a third party,  
10 then the expert should provide whatever information the expert believes can  
11 be disclosed without violating any confidentiality agreements, and the party  
12 seeking to disclose the information to the expert shall be available to meet  
13 and confer with the Producing Party regarding any such confidentiality  
14 obligations.

15           **5.3.3** A party that makes a request and provides the information  
16 specified in paragraphs 5.3.1 or 5.3.2 may disclose the designated material to  
17 the identified in-house counsel or expert unless, within five business days of  
18 delivering the request, the party receives a written objection from the  
19 Producing Party providing detailed grounds for the objection.

20           **5.3.4** All challenges to objections from the Producing Party shall  
21 proceed under L.R. 37-1 through L.R. 37-4. In the event a motion is filed,  
22 disclosure of designated material shall not be made to the proposed in-house  
23 counsel or expert until such time as the Court has made a ruling thereon, and  
24 then, only in accordance with such ruling.



1 **6. IN-HOUSE COUNSEL PROSECUTION AND COMPETITION BAR**

2 Absent written consent from the Producing Party, any in-house counsel who  
 3 receives access to CONFIDENTIAL information shall not have direct  
 4 responsibility for the prosecution of patents or patent applications concerning  
 5 hyaluronic acid compositions containing lidocaine, and their methods of  
 6 manufacture or direct responsibility for (a) research and development; (b)  
 7 marketing; or (c) financial activity relating to hyaluronic acid dermal fillers  
 8 containing lidocaine, for the Receiving Party or its acquirer, successor,  
 9 predecessor, or other affiliate during the pendency of this action and for one year  
 10 after its conclusion, including any appeals. "Prosecution" means drafting,  
 11 amending, advising on the content of, or otherwise affecting the scope or content  
 12 of patent claims or specifications. These prohibitions shall not preclude counsel  
 13 from participating in reexamination or inter partes review proceedings to challenge  
 14 or defend the validity of any patent, but counsel may not participate in the drafting  
 15 of amended claims in any such proceedings.

16 **7. PROTECTED MATERIAL SUBPOENAED OR ORDERED  
 17 PRODUCED IN OTHER LITIGATION**

18 **7.1 Subpoenas and Court Orders.** This Order in no way excuses non-  
 19 compliance with a lawful subpoena or court order. The purpose of the duties  
 20 described in this section is to alert the interested parties to the existence of this  
 21 Order and to give the Producing Party an opportunity to protect its confidentiality  
 22 interests in the court where the subpoena or order issued.

23 **7.2 Notification Requirement.** If a party is served with a subpoena or a  
 24 court order issued in other litigation that compels disclosure of any information or  
 25 items designated in this action as CONFIDENTIAL, that party must:

26 **7.2.1** Promptly notify the Producing Party in writing. Such  
 27 notification shall include a copy of the subpoena or court order;  
 28



1           **7.2.2** Promptly notify in writing the party who caused the subpoena or  
 2           order to issue in the other litigation that some or all of the material covered  
 3           by the subpoena or order is subject to this Order. Such notification shall  
 4           include a copy of this Order; and

5           **7.2.3** Cooperate with all reasonable procedures sought by the  
 6           Producing Party whose material may be affected.

7           **7.3 Wait For Resolution of Protective Order.** If the Producing Party  
 8           timely seeks a protective order, the party served with the subpoena or court order  
 9           shall not produce any information designated in this action as CONFIDENTIAL  
 10          before a determination by the court where the subpoena or order issued, unless the  
 11          party has obtained the Producing Party's permission. The Producing Party shall  
 12          bear the burden and expense of seeking protection of its confidential material in  
 13          that court.

14          **8. UNINTENTIONAL FAILURE TO DESIGNATE**

15          If, through inadvertence, a Producing Party provides any designated material  
 16          pursuant to this litigation without designating and marking the designated material  
 17          as CONFIDENTIAL, the Producing Party may subsequently inform the Receiving  
 18          Party of the confidential nature of the disclosed designated material, and the  
 19          Receiving Party shall treat the disclosed designated material as CONFIDENTIAL  
 20          upon receipt of written notice from the Producing Party, to the extent the  
 21          Receiving Party has not disclosed this designated material. Disclosure of such  
 22          designated material to persons not authorized to receive that material before receipt  
 23          of the confidentiality designation shall not be deemed a violation of this Order.  
 24          However, the Receiving Party agrees to undertake its best efforts to retrieve all  
 25          copies of the designated material, or notes or extracts thereof, in the possession of  
 26          the persons not authorized under this Order to possess such designated material  
 27          and agrees to advise the persons to whom disclosure was made that the material is  
 28



1 confidential and should be treated as provided in this Order. No demonstration or  
 2 proof of error, inadvertence, or excusable neglect by the Producing Party shall be  
 3 required for such redesignation.

#### 4 **9. UNAUTHORIZED DISCLOSURE OF DESIGNATED MATERIAL**

5 If a Receiving Party learns that, by inadvertence or otherwise, it has  
 6 disclosed designated material to any person or in any circumstance not authorized  
 7 under this Order, it must immediately (1) notify in writing the Producing Party of  
 8 the unauthorized disclosures, (2) use its best efforts to retrieve all unauthorized  
 9 copies of the designated material, (3) inform the person or persons to whom  
 10 unauthorized disclosures were made of all the terms of this Order, and (4) use  
 11 reasonable efforts to have such person or persons execute the Agreement to Be  
 12 Bound (Exhibit A).

#### 13 **10. INADVERTENT PRODUCTION OF PRIVILEGED OR 14 OTHERWISE PROTECTED MATERIAL**

15 When a Producing Party gives notice that certain inadvertently produced  
 16 material is subject to a claim of privilege or other protection, the obligations of a  
 17 Receiving Party are those set forth in Federal Rule of Civil Procedure 26(b)(5)(B).  
 18 This provision is not intended to modify whatever procedure may be established in  
 19 an e-discovery order that provides for production without prior privilege review  
 20 pursuant to Federal Rule of Evidence 502(d) and (e).

#### 21 **11. FILING UNDER SEAL**

22 Without written permission from the Producing Party or a Court order, a  
 23 party may not file in the public record in this action any designated material. A  
 24 party seeking to file under seal any designated material must comply with L.R. 79-  
 25 5.1. Filings may be made under seal only pursuant to a Court order authorizing the  
 26 sealing of the specific material at issue. The fact that a document has been  
 27 designated under this Order is insufficient to justify filing under seal. Instead,  
 28



1 parties must explain the basis for confidentiality of each document sought to be  
2 filed under seal. Because a party other than the Producing Party will often be  
3 seeking to file designated material, cooperation between the parties in preparing,  
4 and in reducing the number and extent of, requests for under seal filing is essential.  
5 If a Receiving Party's request to file designated material under seal pursuant to  
6 L.R. 79-5.1 is denied by the Court, then the Receiving Party may file the material  
7 in the public record unless (1) the Producing Party seeks reconsideration within  
8 four days of the denial, or (2) as otherwise instructed by the Court.

## 9 **12. FINAL DISPOSITION**

10 Within 60 days after the final disposition of this action, each party shall  
11 return all designated material to the Producing Party or destroy such material,  
12 including all copies, abstracts, compilations, summaries, and any other format  
13 reproducing or capturing any designated material. A Receiving Party must submit  
14 a written certification to the Producing Party by the 60-day deadline that (1)  
15 identifies (by category, where appropriate) all the designated material that was  
16 returned or destroyed, and (2) affirms that the Receiving Party has not retained any  
17 copies, abstracts, compilations, summaries, or any other format reproducing or  
18 capturing any of the designated material. This provision shall not prevent counsel  
19 from retaining an archival copy of all pleadings, motion papers, trial, deposition,  
20 and hearing transcripts, legal memoranda, correspondence, deposition and trial  
21 exhibits, expert reports, attorney work product, and consultant and expert work  
22 product, even if such materials contain designated material. Any such archival  
23 copies remain subject to this Order.

## 24 **13. NO LIMITATION OF OTHER RIGHTS**

25 This Order shall be without prejudice to the right of any party to oppose  
26 production of any information on any and all grounds other than confidentiality.  
27  
28



1 **14. RELEASE FROM OR MODIFICATION OF THIS ORDER**

2 This Order is entered without prejudice to the right of any party to apply to  
3 the Court at any time for additional protection, or to release, rescind, or modify the  
4 restrictions of this Order.

5 **15. COUNSEL'S RIGHT TO PROVIDE ADVICE**

6 Nothing in this Order shall bar or otherwise restrict any counsel herein from  
7 rendering advice to the counsel's party-client with respect to this action, and in the  
8 course thereof, relying upon an examination of designated material, provided,  
9 however, that in rendering such advice and in otherwise communicating with the  
10 party-client, the counsel shall not disclose any designated material, nor the source  
11 of any designated material, to anyone not authorized to receive such designated  
12 material pursuant to the terms of this Order.

13 IT IS SO STIPULATED, THROUGH COUNSEL OF RECORD.

14  
15 Dated: March 21, 2014

16 By: /s/ Craig E. Countryman  
17 Craig E. Countryman

18 Attorney for Plaintiffs

19 Dated: March 21, 2014

20 By: /s/ William F. Cavanaugh  
21 William F. Cavanaugh

22 Attorney for Defendants

23  
24 IT IS SO ORDERED.

25  
26 DATED: April 07, 2014

27   
28

Jean P. Rosenbluth  
U.S. Magistrate Judge



**SIGNATURE ATTESTATION**

Pursuant to Civil Local Rule 5-4.3.4(a)(2), I attest that counsel for  
Defendants has authorized the filing of this document.

/s/ Craig E. Countryman

---

Craig E. Countryman



**EXHIBIT A**

**AGREEMENT TO BE BOUND**

I, \_\_\_\_\_ [print or type full name], of  
\_\_\_\_\_  
[print or type full address], declare under penalty of perjury that I have read in its entirety  
and understand the Protective Order that was issued by the United States District  
Court for the Central District of California on \_\_\_\_\_ [date] in the case of  
Allergan USA, Inc. et al. v. Medicis Aesthetics, Inc, Case No. 8:13-cv-01436 AG  
(JPRx). I agree to comply with and to be bound by all the terms of this Protective  
Order, and I understand and acknowledge that failure to so comply could expose  
me to sanctions and punishment for contempt. I solemnly promise that I will not  
disclose in any manner any information or item that is subject to this Protective  
Order to any person or entity except in strict compliance with this Order.

I further agree to submit to the jurisdiction of the United States District  
Court for the Central District of California for the purpose of enforcing this Order,  
even if such enforcement proceedings occur after termination of this action.

I hereby appoint \_\_\_\_\_ [print or type full name] of  
\_\_\_\_\_  
[print or type full address and telephone number] as my California agent for service of process in connection with  
this action or any proceedings related to enforcement of this Order.

Date: \_\_\_\_\_

City and State where sworn and signed: \_\_\_\_\_

Printed name: \_\_\_\_\_

[printed name]

Signature: \_\_\_\_\_

[signature]